Paul Hartmann AGSTU:PHH2 62 Current Ratio is 2.22 as of Dec. 2025, which is 0% above its 10-year median of 2.21. GuruFocus rates STU:PHH2 with a GF Score™ of 62/100 and a GF Value™ of €225.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Paul Hartmann AG ranks worse than 57.03% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Paul Hartmann AG's current ratio for the quarter that ended in Dec. 2025 was 2.22.
Paul Hartmann AG has a current ratio of 2.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for Paul Hartmann AG's Current Ratio or its related term are showing as below:
STU:PHH2'
s Current Ratio Range Over the Past 10 Years
Min: 2.12 Med: 2.21 Max: 2.64
Current: 2.22
During the past 13 years, Paul Hartmann AG's highest Current Ratio was 2.64. The lowest was 2.12. And the median was 2.21.
STU:PHH2's Current Ratio is ranked worse than 57.03% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs STU:PHH2: 2.22
Paul Hartmann AG (STU:PHH2) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Paul Hartmann AG Current Ratio Related Terms
Paul Hartmann AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHH2 vs ISRG, BDX, MDLN: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (STU:PHH2) has a Current Ratio of 2.22 as of Dec. 2025. This is near median its historical median of 2.21. Over the past decade, Paul Hartmann AG's Current Ratio has ranged from 2.12 to 2.64. According to the industry distribution chart, Paul Hartmann AG ranks #487 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is Paul Hartmann AG's Current Ratio too high?
Paul Hartmann AG's current Current Ratio of 2.22 is near median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 2.64. The Medical Devices & Instruments industry median Current Ratio is 2.49. Paul Hartmann AG's value of 2.22 is 10.8% below this industry median. Based on the distribution chart, Paul Hartmann AG ranks #487 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Current Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #487 out of 854 companies for Current Ratio. This places Paul Hartmann AG in the lower half of its industry. The industry median Current Ratio is 2.49. Paul Hartmann AG's value of 2.22 is 10.8% below this benchmark. Historically, Paul Hartmann AG's own Current Ratio has ranged from 2.12 to 2.64 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 2.49, Paul Hartmann AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current Current Ratio of 2.22 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current Current Ratio is 2.22, which is near median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €225.24, compared to a current price of €204.00 — trading 9.4% below its estimated fair value. The current Current Ratio is 2.22, which is near median its 10-year median of 2.21 and 10.8% below the Medical Devices & Instruments industry median of 2.49. Paul Hartmann AG's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current Current Ratio is 2.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €204.00 is trading 9.4% below its estimated GF Value™ of €225.24.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for STU:PHH2:
Current Ratio: 2.22 (near median its 10-year median of 2.21)
GF Value™: €225.24 vs. price of €204.00 (9.4% below fair value)
Industry Position: 10.8% below the Medical Devices & Instruments median (#487 of 854)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
62GF Score
Get the complete analysis for STU:PHH2
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
